PALINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
PALISADE BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.34−0.07 (-4.96%)
Close on Oct 19, 2026
- Market cap
- $283.25M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
99.5%
173M of 174M shares
Institutional holders
124
50 new, 21 sold out
Net institutional buying
35M
In Q2 2026
Insider trades, 12 months
8 buys · 4 sales
Net sold $152.67K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah | 9,935,761 | 9.90% | 13G (passive) | Oct 2, 2025 |
| Commodore Capital LP | 9,690,665 | 9.90% | 13G (passive) | Oct 1, 2025 |
| Ting Jia | 9,567,898 | 6.40% | 13G (passive) | Dec 31, 2025 |
| Franklin Resources, Inc. | 9,163,990 | 6.00% | 13G (passive) | Dec 31, 2025 |
| Columbia Management Investment Advisers, LLC | 8,711,385 | 5.30% | 13G (passive) | Mar 31, 2026 |
| William Blank | 8,250,000 | 8.50% | 13G (passive) | Oct 1, 2025 |
| Steven Boyd | 285,417 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| RA Capital Healthcare Fund, L.P. | 17,620,479 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Perceptive Advisors LLC | 15,200,117 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Janus Henderson Group PLC | 14,885,421 | 9.99% | 13G (passive) | Nov 28, 2025 |
| Joseph Edelman | 14,113,863 | 7.90% | 13G (passive) amendment | Mar 31, 2026 |
| Guy Levy | 13,063,687 | 7.50% | 13G (passive) amendment | Jun 30, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. | 12,243,018 | 9.99% | 13G (passive) | Oct 2, 2025 |
| Steven A. Cohen | 10,495,252 | 7.00% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 10,436,760 | 6.00% | 13G (passive) | Jun 30, 2026 |
| David Kroin | 10,012,958 | 9.99% | 13G (passive) | Oct 1, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PALI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. | 13,063,687 | 7.50% | $27.30M | New | 0.94% |
| B Group, Inc. | 11,414,285 | 6.55% | $23.86M | – | 11.20% |
| Ameriprise Financial Inc | 11,081,434 | 6.36% | $23.16M | −428,886 | 0.00% |
| Jupiter Topco LLC | 10,689,452 | 6.13% | $22.39M | New | 0.01% |
| BlackRock, Inc. | 10,436,760 | 5.99% | $21.81M | +8,560,420 | 0.00% |
| Octagon Capital Advisors LP | 10,276,317 | 5.90% | $21.48M | – | 1.93% |
| Perceptive Advisors LLC | 8,425,065 | 4.83% | $17.61M | −503,084 | 0.26% |
| Ra Capital Management, L.P. | 7,124,116 | 4.09% | $14.89M | – | 0.13% |
| Franklin Resources Inc | 5,785,189 | 3.32% | $12.09M | – | 0.00% |
| Point72 Asset Management, L.P. | 5,253,403 | 3.01% | $10.98M | +4,841,631 | 0.01% |
| Boxer Capital Management, LLC | 4,799,875 | 2.75% | $10.03M | – | 0.76% |
| Adage Capital Partners Gp, L.L.C. | 4,500,000 | 2.58% | $9.41M | – | 0.01% |
| Eversept Partners, LP | 4,182,785 | 2.40% | $8.74M | −804,714 | 0.45% |
| Geode Capital Management, LLC | 3,760,485 | 2.16% | $7.86M | +2,214,245 | 0.00% |
| Wellington Management Group Llp | 3,703,936 | 2.13% | $7.74M | +799,025 | 0.00% |
| Goldman Sachs Group Inc | 3,578,020 | 2.05% | $7.48M | −1,795,931 | 0.00% |
| Federated Hermes, Inc. | 3,136,607 | 1.80% | $6.56M | – | 0.01% |
| Squadron Capital Management LLC | 3,000,000 | 1.72% | $6.27M | – | 1.95% |
| Propel Bio Management, LLC | 2,582,388 | 1.48% | $5.40M | +1,467,388 | 2.82% |
| Vestal Point Capital, LP | 2,500,000 | 1.43% | $5.23M | – | 0.12% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 124 | 173M | 99.5% | 50 / 33 | 24 / 21 | 58M | 23M |
| Q1 2026 | 96 | 149M | 85.8% | 31 / 30 | 25 / 20 | 49M | 34M |
| Q4 2025 | 86 | 136M | 78.0% | 75 / 7 | 1 / 1 | 136M | 0M |
| Q3 2025 | 12 | 0M | 0.1% | 2 / 7 | 1 / 1 | 0M | 0M |
| Q2 2025 | 11 | 0M | 0.0% | 3 / 2 | 3 / 5 | 0M | 0M |
| Q1 2025 | 13 | 0M | 0.2% | 4 / 5 | 1 / 1 | 0M | 0M |
| Q4 2024 | 10 | 0M | 0.1% | 2 / 4 | 1 / 1 | 0M | 0M |
| Q3 2024 | 9 | 0M | 0.1% | 1 / 3 | 1 / 0 | 0M | 0M |
| Q2 2024 | 8 | 0M | 0.0% | 8 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PALI | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Russell 2000 ETF | 3,729,134 | 2.14% | $7.79M | 0.01% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 3,136,607 | 1.80% | $5.94M | 0.21% | Jul 31, 2026 |
| Franklin Biotechnology Discovery Fund | 2,119,910 | 1.22% | $4.02M | 0.35% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,722,817 | 0.99% | $3.60M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,610,025 | 0.92% | $3.05M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,117,624 | 0.64% | $2.34M | 0.02% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 773,196 | 0.44% | $1.47M | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 667,004 | 0.38% | $1.41M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 495,848 | 0.28% | $1.04M | 0.07% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 450,543 | 0.26% | $941.63K | 1.22% | Jun 30, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 380,673 | 0.22% | $795.61K | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 358,983 | 0.21% | $680.27K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 275,899 | 0.16% | $576.63K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 269,212 | 0.15% | $570.73K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 246,405 | 0.14% | $514.99K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John David Finley | CEO, CFO, Director | 217,739 | 0.12% | Aug 21, 2026 |
| Mitchell Lawrence Jones | Chief Medical Officer | 94,009 | 0.05% | Jul 8, 2026 |
| Robert Baltera Jr. | Director | 461,904 | 0.27% | Jul 10, 2026 |
| Jordan Michael Zwick | Director | 336,904 | 0.19% | Jun 12, 2026 |
| Donald Allen Williams | Director | 1,512,628 | 0.87% | Jun 12, 2026 |
| Binxian Wei | Director | 613,355 | 0.35% | Jun 12, 2026 |
| Emil Chuang | Director | 612,500 | 0.35% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John David Finley CEO, CFO, Director | Aug 19, 2026 | Gift | −88,400 | – | – | 129,288 |
| John David Finley CEO, CFO, Director | Aug 19, 2026 | Gift | +88,400 | – | – | 88,451 |
| Robert Baltera Jr. Director | Jul 9, 2026 | Buy | +25,000 | $1.96 | $49.00K | 461,904 |
| Robert Baltera Jr. Director | Jul 8, 2026 | Buy | +20,000 | $1.99 | $39.80K | 436,904 |
| John David Finley CEO, CFO, Director | Jul 7, 2026 | Sale | −146,798 | $2.07 | $303.87K | 217,555 |
| John David Finley CEO, CFO, Director | Jul 7, 2026 | Option exercise | +133 | $0.70 | $93 | 217,688 |
| Robert Baltera Jr. Director | Jul 7, 2026 | Buy | +30,000 | $2.03 | $60.90K | 416,904 |
| Mitchell Lawrence Jones Chief Medical Officer | Jul 7, 2026 | Sale | −51,880 | $2.05 | $106.35K | 94,009 |
| John David Finley CEO, CFO, Director | Jul 6, 2026 | Option exercise | +335,167 | – | – | 364,353 |
| Robert Baltera Jr. Director | Jul 6, 2026 | Buy | +20,000 | $2.05 | $41.00K | 386,904 |
| Mitchell Lawrence Jones Chief Medical Officer | Jul 6, 2026 | Option exercise | +131,167 | – | – | 145,889 |
| Robert Baltera Jr. Director | Jul 2, 2026 | Buy | +10,000 | $1.98 | $19.80K | 366,904 |
| Robert Baltera Jr. Director | Jul 1, 2026 | Buy | +20,000 | $1.98 | $39.60K | 356,904 |
| Robert Baltera Jr. Director | Jun 10, 2026 | Award | +336,904 | – | – | 336,904 |
| Jordan Michael Zwick Director | Jun 10, 2026 | Award | +336,904 | – | – | 336,904 |
| Donald Allen Williams Director | Jun 10, 2026 | Award | +1,498,900 | – | – | 1,509,628 |
| Donald Allen Williams Director | Jun 10, 2026 | Option exercise | +60,666 | – | – | 1,570,294 |
| Emil Chuang Director | Jun 10, 2026 | Option exercise | +20,200 | – | – | 612,500 |
| Emil Chuang Director | Jun 10, 2026 | Award | +592,300 | – | – | 592,300 |
| Binxian Wei Director | Jun 10, 2026 | Option exercise | +20,200 | – | – | 613,355 |
| Binxian Wei Director | Jun 10, 2026 | Award | +592,300 | – | – | 593,155 |
| Mitchell Lawrence Jones Chief Medical Officer | Feb 12, 2026 | Sale | −1,989 | $1.75 | $3.48K | 13,263 |
| John David Finley CEO, CFO, Director | Feb 12, 2026 | Sale | −3,896 | $1.75 | $6.82K | 27,353 |
| Mitchell Lawrence Jones Chief Medical Officer | Feb 11, 2026 | Option exercise | +8,000 | – | – | 15,252 |
| John David Finley CEO, CFO, Director | Feb 11, 2026 | Option exercise | +13,333 | – | – | 31,249 |
| Donald Allen Williams Director | Jan 16, 2026 | Buy | +5,000 | $1.67 | $8.35K | 10,728 |
| Donald Allen Williams Director | Jan 9, 2026 | Buy | +5,000 | $1.88 | $9.40K | 5,728 |
| Binxian Wei Director | Nov 21, 2024 | Option exercise | +388 | – | – | 855 |
| Donald Allen Williams Director | Nov 21, 2024 | Option exercise | +388 | – | – | 728 |
| Donald Allen Williams Director | Jun 11, 2024 | Option exercise | +340 | – | – | 340 |
| Binxian Wei Director | Jun 11, 2024 | Option exercise | +465 | – | – | 467 |
| John David Finley CEO, CFO, Director | May 28, 2024 | Option exercise | +2,111 | – | – | 14,079 |
| John David Finley CEO, CFO, Director | May 28, 2024 | Option exercise | +1,622 | – | – | 10,059 |
| John David Finley CEO, CFO, Director | May 28, 2024 | Tax withholding | −467 | $4.76 | $2.22K | 9,592 |
| John David Finley CEO, CFO, Director | May 28, 2024 | Option exercise | +3,335 | – | – | 12,927 |
| John David Finley CEO, CFO, Director | May 28, 2024 | Tax withholding | −959 | $4.76 | $4.56K | 11,968 |
| John David Finley CEO, CFO, Director | May 28, 2024 | Tax withholding | −607 | $4.76 | $2.89K | 13,472 |
| Mitchell Lawrence Jones Chief Medical Officer | May 28, 2024 | Tax withholding | −461 | $4.76 | $2.19K | 3,852 |
| Mitchell Lawrence Jones Chief Medical Officer | May 28, 2024 | Option exercise | +2,735 | – | – | 3,568 |
| Mitchell Lawrence Jones Chief Medical Officer | May 28, 2024 | Tax withholding | −810 | $4.76 | $3.86K | 2,758 |
| Mitchell Lawrence Jones Chief Medical Officer | May 28, 2024 | Option exercise | +1,555 | – | – | 4,313 |
| Donald Allen Williams Director | May 28, 2024 | Buy | +1,000 | $4.86 | $4.86K | 1,000 |
| John David Finley CEO, CFO, Director | May 24, 2024 | Buy | +1,000 | $4.81 | $4.81K | 8,437 |
| John David Finley CEO, CFO, Director | May 20, 2024 | Award | +666 | $4.97 | $3.31K | 7,437 |
| Mitchell Lawrence Jones CEO, CFO, Director | May 6, 2024 | Tax withholding | −90 | $8.46 | $761 | 724 |
| Mitchell Lawrence Jones CEO, CFO, Director | May 6, 2024 | Option exercise | +156 | – | – | 880 |
| Mitchell Lawrence Jones CEO, CFO, Director | May 6, 2024 | Tax withholding | −47 | $8.46 | $398 | 833 |
| Mitchell Lawrence Jones CEO, CFO, Director | May 6, 2024 | Option exercise | +304 | – | – | 814 |
| John David Finley CEO, CFO, Director | May 6, 2024 | Tax withholding | −67 | $8.46 | $567 | 6,621 |
| John David Finley CEO, CFO, Director | May 6, 2024 | Option exercise | +211 | – | – | 6,832 |
| John David Finley CEO, CFO, Director | May 6, 2024 | Tax withholding | −61 | $8.46 | $516 | 6,771 |
| John David Finley CEO, CFO, Director | May 6, 2024 | Option exercise | +232 | – | – | 6,688 |
| John David Finley CEO, CFO, Director | Mar 11, 2024 | Option exercise | +5,558 | – | – | 96,849 |
| James R. Neal Director | Feb 9, 2024 | Option exercise | +5,100 | – | – | 5,100 |
| James R. Neal Director | Feb 9, 2024 | Option exercise | +5,820 | – | – | 10,920 |
| Stephanie Diaz Director | Feb 8, 2024 | Option exercise | +5,820 | – | – | 12,800 |
| Stephanie Diaz Director | Feb 8, 2024 | Option exercise | +6,980 | – | – | 6,980 |
| Robert J. Trenschel Director | Feb 8, 2024 | Option exercise | +5,820 | – | – | 10,920 |
| Robert J. Trenschel Director | Feb 8, 2024 | Option exercise | +5,100 | – | – | 5,100 |
| Cristina Csimma Director | Feb 8, 2024 | Option exercise | +6,980 | – | – | 7,042 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John David Finley Officer | Jul 7, 2026 | 146,798 | $303.34K | Jul 7, 2026 | RSU Vesting |
| Mitchell Lawrence Jones Officer | Jul 7, 2026 | 53,000 | $108.12K | Jul 7, 2026 | RSU |